OPTIC NERVE IMPLANTS

• US 20090227933A1
• Filed: 04/07/2008
• Published: 09/10/2009
• Est. Priority Date: 02/18/2003
• Status: Active Grant

• Current Assignee: S. K. Pharmaceuticals, Inc.
• Original Assignee: SK Biopharmaceuticals Co., Ltd. (SK Inc.)
• Inventors: Karageozian, Hampar L.
• Granted Patent: US 8,012,115 B2
• Time in Patent Office: Days
• US Class Current: 604/8
• CPC Class Codes: A61F 9/0008 Introducing ophthalmic products into the ocular cavity or retaining products therein putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048

Abstract

Methods and devices for delivering therapeutic substances into the eye. An implant containing the therapeutic substance is implanted at least partially within the optic nerve and the therapeutic substance then elutes from the implant. The implant may have a lumen or it may be solid.

Claims

1. A method for delivering a therapeutic substance into the eye of a human or animal subject, said method comprising the steps of:

A) providing an implant that contains a quantity of the substance; and

B) inserting the implant into the optic nerve such that a therapeutic amount of the substance will elute from the implant.

2. A method according to claim 1 wherein the implant has a lumen and additionally functions as a tubular shunt such that fluid from the interior of the eye will enter one end of the shunt and said fluid will exit the other end of the shunt either i) at a location within the optic nerve or ii) at a location within the subarachnoid space.

3. A method according to claim 2 wherein the implant comprises a tube having a proximal end, a distal end and least one tissue engaging member formed on the implant to deter unwanted movement of the implant after it has been implanted.

4. A method according to claim 3 wherein the at least one tissue engaging member comprises a barb or barb like structure that allows the shunt to be advanced through tissue in a distal direction but engages the tissue in a manner that deters subsequent retraction of the shunt in a proximal direction.

5. A method according to claim 2 wherein the implant comprises a tube having a proximal end, a distal end and a flange member formed on the proximal end thereof.

6. A method according to claim 2 wherein the implant comprises a tube having a valve associated therewith, said valve being operative to perform at least one valving function selected from the group consisting of a) allowing fluid to flow out of the eye but deterring fluid form backflowing into the eye and b) allowing fluid to flow out of the eye only when the fluid pressure exceeds a predetermined maximum pressure.

7. A method according to claim 2 wherein the implant comprises a tube having a proximal end, a distal end and at least one shielding member associated therewith to deter foreign matter or cells from clogging the tube.

8. A method according to claim 7 wherein the shielding member comprises a semi-permeable membrane constructed and positioned such that fluid flowing out of the distal end of the tube will diffuse outwardly through the membrane but foreign matter and cells will not diffuse inwardly through the membrane and into the distal end of the tube.

9. A method according to claim 1 wherein the implant is devoid of a lumen.

10. A method according to claim 1 wherein the therapeutic substance comprises a corticosteroid.

11. A method according to claim 1 wherein the implant contains from about 1 to about 100 mg triamcinolone acetonide.

12. A method according to claim 1 wherein the method is carried out to treat macular degeneration.

13. A method according to claim 1 wherein step B is performed without a vitrectomy.

14. A method according to claim 13 wherein step B is performed by delivering the implant through a needle that is inserted intot he optic nerve through the in tact vitreous.